Review article: The histological assessment of disease activity in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 8, 2015, Pages 957-967

  Marchal Bressenot, A ^a   Riddell, R H ^b   Boulagnon Rombi, C ^a   Reinisch, W ^c   Danese, S ^d   Schreiber, S ^e   Peyrin Biroulet, L ^f  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID;

ABSCESS; CLINICAL FEATURE; COLON BIOPSY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY; DISEASE SEVERITY; GEBOES INDEX; GENERAL ASPECTS OF DISEASE; GRAMLICH INDEX; GUPTA INDEX; HEALING; HISTOLOGICAL HEALING; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; INTESTINE CRYPT ABSCESS; INTESTINE EPITHELIUM; INTESTINE ULCER; LEUKOCYTE COUNT; NEUTROPHIL CHEMOTAXIS; PLASMACYTOSIS; PREDICTION; PRIORITY JOURNAL; QUIESCENT DISEASE; RECTUM BIOPSY; RELAPSE; REMISSION; REPRODUCIBILITY; REVIEW; RILEY INDEX; ULCERATIVE COLITIS; BIOPSY; DISEASE COURSE; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RECTUM; RECURRENT DISEASE; WOUND HEALING;

BIOPSY; COLITIS, ULCERATIVE; DISEASE PROGRESSION; HISTOLOGICAL TECHNIQUES; HUMANS; MALE; MIDDLE AGED; RECTUM; RECURRENCE; RESEARCH DESIGN; WOUND HEALING;

EID: 84941732293     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13375     Document Type: Review

References (67)

1. Peyrin-Biroulet L, Ferrante M, Magro F, et al., Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011; 5: 477-83.
2. Bryant RV, Winer S, Travis SPL, Riddell RH,. Systematic review: histological remission in inflammatory bowel disease. Is "complete" remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014; 8: 1582-97.
3. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME,. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
4. Wright R, Truelove SR,. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966; 11: 847-57.
5. Bryant RV, Burger DC, Delo J, et al., Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2015; doi: 10.1136/gutjnl-2015-309598 [Epub ahead of print].
6. Gupta RB, Harpaz N, Itzkowitz S, et al., Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-105; quiz 1340-1341.
7. Rutter M, Saunders B, Wilkinson K, et al., Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-9.
8. Hartmann F, Stein J,; BudMesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2010; 32: 368-76.
9. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ,. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; CD004115.
10. Molander P, Sipponen T, Kemppainen H, et al., Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. J Crohns Colitis 2013; 7: 730-5.
11. Hanauer SB, Robinson M, Pruitt R, et al., Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 1998; 115: 525-32.
12. Truelove SC, Richards WC,. Biopsy studies in ulcerative colitis. Br Med J 1956; 1: 1315-8.
13. Florén CH, Benoni C, Willén R,. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 1987; 22: 459-62.
14. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R,. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47: 404-9.
15. Gomes P, du Boulay C, Smith CL, Holdstock G,. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92-5.
16. Hanauer S, Schwartz J, Robinson M, et al., Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol 1993; 88: 1188-97.
17. Korelitz BI, Sommers SC,. Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and mucosal cell counts. Am J Dig Dis 1976; 21: 441-7.
18. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE,. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533-7.
19. Mosli MH, Feagan BG, Sandborn WJ, et al., Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis 2014; 20: 564-75.
20. Gramlich T, Petras RE,. Pathology of inflammatory bowel disease. Semin Pediatr Surg 2007; 16: 154-63.
21. Bressenot A, Geboes K, Vignaud J-M, Gueant JL, Peyrin-Biroulet L,. Microscopic features for initial diagnosis and disease activity evaluation in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1745-52.
22. Peyrin-Biroulet L, Bressenot A, Kampman W,. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 2014; 12: 929-34.
23. Langner C, Magro F, Driessen A, et al., The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Arch 2014; 464: 511-27.
24. Bressenot A, Salleron J, Bastien C, Danese S, Boulagnon-Rombi C, Peyrin-Biroulet L,. Comparing histological activity indexes in UC. Gut 2015; 64: 1412-18.
25. Jenkins D, Balsitis M, Gallivan S, et al., Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997; 50: 93-105.
26. Odze R, Antonioli D, Peppercorn M, Goldman H,. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993; 17: 869-75.
27. Bitton A, Peppercorn MA, Antonioli DA, et al., Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20.
28. Mosli MH, Feagan BG, Zou G, et al., Reproducibility of histological assessments of disease activity in UC. Gut 2014; doi: 10.1136/gutjnl-2014-307536 [Epub ahead of print].
29. Jenkins D, Goodall A, Drew K, Scott BB,. What is colitis? Statistical approach to distinguishing clinically important inflammatory change in rectal biopsy specimens. J Clin Pathol 1988; 41: 72-9.
30. Dubucquoi S, Janin A, Klein O, et al., Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. Gut 1995; 37: 242-6.
31. Tanaka M, Riddell RH, Saito H, Soma Y, Hidaka H, Kudo H,. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis. Scand J Gastroenterol 1999; 34: 55-67.
32. Villanacci V, Antonelli E, Reboldi G, Salemme M, Casella G, Bassoti G,. Endoscopic biopsy samples of naïve "colitides" patients: role of basal plasmacytosis. J Crohns Colitis 2014; 8: 1438-43.
33. Travis SPL, Higgins PDR, Orchard T, et al., Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 34: 113-24.
34. Panaccione R, Colombel J-F, Louis E, Peyrin-Biroulet L, Sandborn WJ,. Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis 2013; 19: 1645-53.
35. Villanacci V, Antonelli E, Geboes K, Casella G, Bassotti G,. Histological healing in inflammatory bowel disease: a still unfulfilled promise. World J Gastroenterol 2013; 19: 968-78.
36. Freeman HJ,. Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol 2010; 16: 15-20.
37. Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V,. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis 2013; 45: 969-77.
38. Mayer L, Sandborn WJ, Stepanov Y, et al., Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut 2014; 63: 442-50.
39. Bessissow T, Lemmens B, Ferrante M, et al., Prognostic value of serologic and histologic markers on long-term outcomes in ulcerative colitis patients with mucosal healing. Abstract UEGW, 2012.
40. Truelove SC, Hambling MH,. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial. Br Med J 1958; 2: 1072-7.
41. Sherlock ME, Seow CH, Steinhart AH, Griffiths AM,. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; (10): CD007698.
42. Green JRB, Mansfield JC, Gibson JA, Kerr GD, Thornton PC,. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 61-8.
43. Kruis W, Kiudelis G, Rácz I, et al., Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58: 233-40.
44. Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD,. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 69-77.
45. Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M,. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005; 11: 421-7.
46. Rao SS, Dundas SA, Holdsworth CD, Cann PA, Palmer KR, Corbett CL,. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study Gut 1989; 30: 675-9.
47. Chey WY,. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001; 7 (Suppl. 1): S30-3.
48. Tursi A, Elisei W, Picchio M, et al., Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab. Clin Res Hepatol Gastroenterol 2015; 39: 107-13.
49. Sandborn WJ, Travis S, Moro L, et al., Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143: 1218-26. e1-2.
50. Travis SPL, Danese S, Kupcinskas L, et al., Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63: 433-41.
51. Schumacher G, Kollberg B, Sandstedt B,. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Histologic course during the 1st year after presentation. Scand J Gastroenterol 1994; 29: 318-32.
52. Neurath MF,. Animal models of inflammatory bowel diseases: illuminating the pathogenesis of colitis, ileitis and cancer. Dig Dis Basel Switz 2012; 30 (Suppl. 1): 91-4.
53. Rubio CA, Johansson C, Uribe A, Kock Y,. A quantitative method of estimating inflammation in the rectal mucosa IV. Ulcerative colitis in remission. Scand J Gastroenterol 1984; 19: 525-30.
54. Price AB, Morson BC,. Inflammatory bowel disease: the surgical pathology of Crohn's disease and ulcerative colitis. Hum Pathol 1975; 6: 7-29.
55. Serafini EP, Kirk AP, Chambers TJ,. Rate and pattern of epithelial cell proliferation in ulcerative colitis. Gut 1981; 22: 648-52.
56. Lampinen M, Rönnblom A, Amin K, et al., Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 2005; 54: 1714-20.
57. Azad S, Sood N, Sood A,. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol 2011; 17: 194-8.
58. Moum B, Ekbom A, Vatn MH, Elgjo K,. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 1999; 94: 1564-9.
59. Levine TS, Tzardi M, Mitchell S, Sowter C, Price AB,. Diagnostic difficulty arising from rectal recovery in ulcerative colitis. J Clin Pathol 1996; 49: 319-23.
60. Bentley E, Jenkins D, Campbell F, Warren B,. How could pathologists improve the initial diagnosis of colitis? Evidence from an international workshop. J Clin Pathol 2002; 55: 955-60.
61. Geboes K, Ectors N, D'Haens G, Rutgeerts P,. Is ileoscopy with biopsy worthwhile in patients presenting with symptoms of inflammatory bowel disease? Am J Gastroenterol 1998; 93: 201-6.
62. McHugh JB, Appelman HD, McKenna BJ,. The diagnostic value of endoscopic terminal ileum biopsies. Am J Gastroenterol 2007; 102: 1084-9.
63. Magro F, Langner C, Driessen A, et al., European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013; 7: 827-51.
64. Kleer CG, Appelman HD,. Ulcerative colitis: patterns of involvement in colorectal biopsies and changes with time. Am J Surg Pathol 1998; 22: 983-9.
65. Surawicz CM, Belic L,. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology 1984; 86: 104-13.
66. Surawicz CM,. Serial sectioning of a portion of a rectal biopsy detects more focal abnormalities: a prospective study of patients with inflammatory bowel disease. Dig Dis Sci 1982; 27: 434-6.
67. Surawicz CM, Meisel JL, Ylvisaker T, Saunders DR, Rubin CE,. Rectal biopsy in the diagnosis of Crohn's disease: value of multiple biopsies and serial sectioning. Gastroenterology 1981; 80: 66-71.